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Treatment of Histoplasmosis
Felix Bongomin, Richard Kwizera, Joseph Baruch Baluku, 
Lucy Grace Asio and Akaninyene A. Otu
Abstract
Histoplasmosis, caused by the thermally dimorphic fungus Histoplasma capsula-
tum, is an uncommon multisystem disease with a global distribution. The spectrum 
of clinical manifestations ranges from an asymptomatic or minimally symptomatic 
acute pulmonary disease following inhalation of a large inoculum of Histoplasma 
microconidia to chronic pulmonary disease in patients with underlying structural 
lung disease. It also extends to acute progressive disseminated disease in patients with 
severe immunodeficiency. Generally, antifungal therapy is indicated for patients with 
progressive acute pulmonary histoplasmosis, chronic pulmonary histoplasmosis and 
acute progressive disseminated histoplasmosis. In immunocompetent patients, acute 
pulmonary histoplasmosis may be a self-limiting disease without the need for systemic 
antifungal therapy. Oral triazole antifungal drugs alone are recommended for less 
severe disease. However, moderate-to-severe acute pulmonary histoplasmosis requires 
intravenous amphotericin B therapy for at least 1–2 weeks followed by oral itraconazole 
for at least 12 weeks. For acute progressive disseminated histoplasmosis, intravenous 
amphotericin B therapy is given for at least 2 weeks (4–6 weeks if meningeal involve-
ment) or until a patient can tolerate oral therapy, followed by oral itraconazole (or an 
alternative triazole) for at least 12 months. Chronic cavitary pulmonary histoplasmosis 
is treated with oral itraconazole for 1–2 years. There is insufficient evidence to support 
the use of isavuconazole or the echinocandins for the treatment of histoplasmosis.
Keywords: Histoplasma capsulatum, histoplasmosis, itraconazole,  
amphotericin B, HIV
1. Introduction
Histoplasmosis is an uncommon endemic mycosis caused by the fungus 
Histoplasma capsulatum that usually causes an asymptomatic infection but occa-
sionally results in severe multisystem disease [1, 2]. Two main varieties of the 
saprophytic, thermally dimorphic fungus of the genus Histoplasma affect humans; 
Histoplasma capsulatum var. capsulatum and Histoplasma capsulatum var. duboisii 
[3–5]. Histoplasmosis affects over 10,000 people globally; it is neglected, worry-
ingly under-diagnosed, and often misdiagnosed as cancer or tuberculosis with 
fatal consequences [6–8]. The spectrum of the clinical manifestation of histoplas-
mosis is very broad, ranging from an asymptomatic or minimally symptomatic 
acute pulmonary disease following inhalation of a large inoculum of Histoplasma 
 microconidia to chronic pulmonary disease in patients with underlying structural 
lung disease, to acute progressive disseminated disease in patients with severe  
immunodeficiency [9–13]. In immunocompetent patients, acute histoplasmosis is 
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typically a self-limiting disease with no need for antifungal therapy [14]. Pneumonia 
remains the most common disease presentation but extrapulmonary dissemination 
can occur, especially in immunocompromised patients [12]. A definite diagnosis 
of histoplasmosis is based on the isolation of the organisms in fungal culture [15]. 
Rapid detection of the H. capsulatum polysaccharide antigen using enzyme immu-
noassay (EIA) in urine, blood or bronchoalveolar lavage fluid is also available and 
very useful especially among immunocompromised patients with disseminated or 
acute pulmonary disease [13, 16]. Serologic testing for antibodies can be achieved by 
EIA, immunodiffusion, and complement fixation [13, 16, 17]. These antibody tests 
may be falsely negative in immunosuppressed patients and are most valuable when 
combined with a compatible clinical presentation and epidemiologic risk factors.
This chapter provides an overview of the currently available treatment options 
for the different manifestations of histoplasmosis.
2. Antifungal agents used in the treatment of histoplasmosis
Histoplasmosis is primarily treated with 2 distinct classes of antifungal agents: 
The triazoles and the polyenes. Data is lacking on the use of the echinocandins for 
the treatment of histoplasmosis.
2.1 Triazole
The triazole class of antifungals examples of which includes drug like fluco-
nazole, itraconazole, voriconazole, posaconazole and isavuconazole [18, 19]. Of 
these, itraconazole is the drug of choice for the treatment of the various forms of 
histoplasmosis as a sole therapy or as a step-down therapy following amphotericin B 
infusion [13, 14, 20].
Triazole antifungals inhibit the cytochrome P450-dependent enzyme 14-alpha-
lanosterol demethylase (CYP51) encoded by the ERG11 gene that converts lanosterol to 
ergosterol in the cell membrane, inhibiting fungal growth and replication (fungistatic) 
[18, 19]. Drug-drug and drug-food interactions, as well as side effects are major issues 
associated with itraconazole therapy. Common side effects of itraconazole include 
drug-induced hepatitis, gastrointestinal discomfort, heart failure, ankle edema, alo-
pecia, erectile dysfunction, gynaecomastia, peripheral neuropathy, visual disturbance 
and headaches [21]. Itraconazole interacts with agents used in the treatment of HIV 
(especially, nevirapine) and tuberculosis (especially, rifampicin) leading to decreased 
or increased exposures to itraconazole and therefore increased risk of hepatotoxicity. 
With the exception of fluconazole, voriconazole and posaconazole are used as alterna-
tive agents for the treatment of histoplasmosis if there is a contraindication to the use 
of itraconazole [13, 14, 20]. However, to the best of our knowledge, there is no data to 
support the use of isavuconazole for the treatment of histoplasmosis.
2.2 Polyene
The polyene antibiotic, amphotericin B derived from the fermentation product 
of the filamentous bacteria, Streptomyces nodosus is a broad-spectrum antifungal 
agent administered as deoxycholate (conventional amphotericin B) or liposomal 
formulation [18, 19].
In its mechanism of action, amphotericin B preferentially binds ergosterol in 
the fungal cell membrane (and to a lesser extent, cholesterol in cell membrane of 
humans) to form channels through which small molecules leak from the inside of the 
fungal cell to the outside, resulting in death of the fungal cell (fungicidal) [18, 19].
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Common side effects of amphotericin B include, acute infusion-related reactions 
characterised by nausea, vomiting, rigors, fever, hyper or hypotension, and hypoxia 
mainly driven by the effects of amphotericin B on pro-inflammatory cytokine 
production. Nephrotoxicity is another very important side effect of amphotericin 
B occurring in about 34–60% of patients. Blood disorders, especially anaemia 
and electrolyte disturbances, especially hypomagnesaemia and hypokalemia are 
common but can be part of the rare Fanconi syndrome. Other side effects include 
infusion site phlebitis, and acute kidney injury [21].
3. Overview of antifungal treatment of histoplasmosis
It is important to understand the indications and the choices of antifungal agents 
in the treatment of histoplasmosis. Manifestations of histoplasmosis that are a typi-
cally treated include moderate to severe acute pulmonary histoplasmosis, symp-
tomatic chronic cavitary pulmonary histoplasmosis, acute progressive disseminated 
disease, and histoplasmosis in immunocompromised individuals [12, 13], (Table 1). 
Treatment is also indicated for complications of histoplasmosis such as mediastinal 
granulomas and adenitis [14], (Table 1). Itraconazole can be used for the treatment 
of symptomatic immunocompetent patients with indolent non-meningeal infec-
tion, including chronic cavitary pulmonary histoplasmosis [12, 13]. Itraconazole is 
also used as a step-down oral agent following initial treatment of severe disease with 
amphotericin B [12, 13]. Itraconazole is administered at a dose 200 mg 3 times daily 
for 3 days, as loading dose and then 200 mg once or twice daily, for maintenance 
therapy [12, 13]. Duration of itraconazole therapy depends on the histoplasmosis 
syndrome being managed (Table 1).
Amphotericin by intravenous infusion is the drug of choice for the initial treat-
ment of fulminant or moderate to severe infections, followed by a course of oral. 
Following successful treatment, itraconazole can be used for secondary prophylaxis 
against relapse until immune reconstitution is realised [12, 13]. The deoxycholate 
formulation of amphotericin B is administered at a dose of 0.7–1.0 mg/kg daily 
by intravenous infusion, meanwhile the lipid formulation of amphotericin B can 
be administered at a higher dose of 3.0–5.0 mg/kg daily. Liposomal formulation is 
preferred to the deoxycholate due to its superior side effect profile, better response 
rate and survival benefit [14, 20].
3.1 Central nervous system histoplasmosis
There are no known prospective studies that have evaluated treatment of central 
nervous system (CNS) histoplasmosis. Treatment recommendations are guided by 
several case reports, retrospective case series and expert opinion [12, 13].
Liposomal amphotericin B achieves higher CNS concentrations than 
 deoxycholate formulations and together with triazoles, is the recommended 
therapy for CNS histoplasmosis [22]. While the choice of the optimal triazole 
is in doubt, there is evidence from an animal model to suggest that fluconazole 
may be antagonistic when combined with amphotericin B [23]. Voriconazole 
could have a role among patients with good performance status as monotherapy 
or in combination with amphotericin B, but the evidence is limited and the 
occurrence of hepatotoxicity and hypersensitivity may limit its use [24–26]. 
One case series of 11 cases reported a morbidity free survival of 54.5% when 
patients were treated with intravenous amphotericin B deoxycholate for 
8 weeks followed by maintenance therapy with fluconazole or itraconazole for 
12–18 months [27].
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Histoplasmosis 
syndrome or 
complication
Risk factor Clinical 
time-course
Indication for treatment Treatment Antifungal therapy 
duration
Acute progressive 
disseminated 
histoplasmosis
Immunosuppression such as 
advanced HIV disease
1–2 weeks Always Mild disease Itraconazole 12 months followed by 
maintenance antifungal 
suppression until 
immune recovery
Moderate 
to severe 
disease
Amphotericin B for 1–2 weeks in 
non-meningeal and 4–6 weeks 
in meningeal disease followed 
by itraconazole as step-down 
therapy
Acute pulmonary 
histoplasmosis
High inoculum exposure to 
Histoplasma conidia
1–2 weeks Moderate or severe disease 
or immunosuppressed 
patient
Mild disease Itraconazole 12 weeks
Severe 
disease
Amphotericin B for 1–2 weeks 
followed by itraconazole as step-
down therapy
Subacute pulmonary 
histoplasmosis
Low inoculum exposure to 
Histoplasma conidia
Weeks to 
months
If symptoms last 
>1 months or 
immunosuppressed 
patient
Itraconazole 6–12 weeks
Chronic cavitary 
pulmonary 
histoplasmosis
Chronic obstructive 
pulmonary disease and other 
lung diseases Smoking
Months to 
years
Always Itraconazole 1–2 years and until 
radiologic resolution or 
stabilisation
Mediastinal adenitis Reactive and enlarged 
mediastinal lymph nodes
Early 
complication
If compressive symptoms 
present or adenitis last 
>1 months
Itraconazole and steroids 6–12 weeks
Mediastinal 
granuloma
Coalesced necrotic 
mediastinal lymph nodes
Early or late 
complication
If compressive symptoms 
present
Surgery and itraconazole 6–12 weeks
Mediastinal fibrosis Fibrosis of mediastinal 
structures
Late 
complication
If compressive symptoms 
present
Stenting, arterial embolization or surgery Not applicable
Table 1. 
Treatment of histoplasmosis syndromes and their complications [13, 14].
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The Infectious Diseases Society of America (IDSA) recommends treating CNS 
disease with liposomal amphotericin B (3.0–5.0 mg/kg daily for a total of 175 mg/kg  
given over 4–6 weeks), followed by a maintenance phase with itraconazole for 
at least a year at a dose of 200 mg, given 2–3 times a day [14]. Resolution of CSF 
abnormalities, including a negative antigen test is the recommended treatment target. 
Specific recommendations for CSF monitoring are: (a) worsening disease in the 
initial 2 weeks of therapy or lack of improvement by 1 month of therapy, in order to 
re-evaluate the diagnosis, (b) when amphotericin B is being replaced by a triazole, 
(c) if relapse is suspected and (d) after 1 year of therapy, to make the decision of 
treatment continuation or stoppage. Therapeutic drug monitoring for itraconazole 
is recommended during treatment to ensure adequate drug exposure. Treatment 
recommendations for histoplasmosis meningitis or CNS masses are the same. Also, 
for patients with concurrent pulmonary disease, chronic suppressive therapy with 
200 mg of itraconazole, given once a day, is indicated until the patient’s immune 
system is reconstituted [13, 14, 28].
The role of steroids is not well described, although case reports indicate they 
can be successfully used [14] . Similarly, routine brain or spinal cord surgery is not 
recommended by IDSA but is chronicled in case reports [14, 28]. Hydrocephalus 
complicating CNS histoplasmosis may be managed with shunt placement when the 
patient has received at least 2 weeks of amphotericin B therapy [22]. The manage-
ment of increased intracranial pressure and the long-term sequelae that require 
rehabilitation is similar to what is done for stroke and brain tumours [14, 28].
In a sizable cohort of patients, the one-year survival of patients with CNS 
histoplasmosis was reported to be 75% among patients who were initially treated 
with liposomal or deoxycholate formulations of amphotericin [28].
3.2 Histoplasmosis in pregnancy
All presenting clinical syndromes of histoplasmosis in pregnancy require 
antifungal therapy due to the increased risk of trans-placental transmission of the 
infection to the developing fetus [29]. Preferably, pregnant women can be treated 
with amphotericin B preparations for 4–6 weeks. Lipid formulation of amphoteri-
cin B is given at a dose of 3–5 mg/kg/day. For pregnant women with low risk for 
nephrotoxicity, amphotericin B deoxycholate (0.7–1.0 mg/kg/day) may be offered 
as a substitute [14, 30]. Coupled with this, post-partum monitoring of the child 
for any evidence of the infection is vital. In any case of the newborn showing signs 
of histoplasmosis infection, it is recommended that treatment of amphotericin B 
deoxycholate (1 mg/kg/day) is given for 4 weeks [14, 30].
Itraconazole is generally considered teratogenic to the growing fetus and is 
therefore best avoided in pregnancy. However, itraconazole may be considered for 
treatment in pregnant women with systemic histoplasmosis, but only after the first 
trimester [31, 32]. Amphotericin B therefore remains the drug of choice in manag-
ing histoplasmosis in pregnancy, as azole antifungals should generally be avoided.
3.3  Histoplasmosis-associated immune reconstitution inflammatory syndrome 
in the context of human immunodeficiency virus disease
Immune reconstitution inflammatory syndrome (IRIS) is a spectrum of inflam-
matory disorders linked with paradoxical worsening of pre-existing infectious 
diseases (previously diagnosed or subclinical) in HIV-infected patients. It typically 
follows, the initiation of antiretroviral therapy (ART): whereby the ART improves 
the patient’s immune system enough to mount an inflammatory response tends to 
unmask the underlying infectious processes, such as histoplasmosis [33–36].
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In studies done among HIV patients, histoplasmosis-associated - IRIS was 
associated with histoplasmosis; IRIS was reported to be uncommon with incidence 
rates of 0.74 cases per 1000 HIV-infected person-years 0.5% [37–39]. However 
according to another study among 271 patients, the emergence of IRIS tended to be 
quite common in people with HIV and disseminated histoplasmosis; whether the 
IRIS is triggered by the Histoplasma or other co-infections, is still unclear [40].
For HIV patients with histoplasmosis to be considered to have histoplasmosis - 
associated IRIS, they should fulfil most or all of the following criteria: AIDS with 
low pretreatment CD4 count (≤100 cells/μL), a positive immunological and 
virological response to ART, clinical manifestations of an inflammatory condi-
tion, association between ART initiation and appearance of clinical features of 
the inflammatory condition and; absence of evidence of ART resistance, patient 
non-compliance, drug allergy or adverse reactions, a concomitant non- fungal 
infection, or decreased drug levels due to malabsorption or drug-drug interactions 
[36, 38, 41–43].
The clinical manifestations vary from case to case, and they commonly include 
fever, lymphadenopathy, mucocutaneous lesions, and disseminated disease. The 
timeline of occurrence from initiation of ART is also varied from a few days to 
months, and symptoms can set in when the patient is already on the ART course or 
when the ART is just introduced [39, 44, 45]. Histoplasmosis-associated IRIS in HIV 
patients may have a predilection for females over males, with one study showing 
that it was four times more frequent in females than males [39].
If the symptoms of IRIS are mild, the patient is managed symptomatically. The 
role of steroids in treating histoplasmosis-IRIS is yet unclear [39].
However if the presentation is severe, corticosteroids may be used as they have 
been seen to be of benefit in TB-associated IRIS, though they should be used with 
caution [46].
Once a patient exhibits features of IRIS while already on effective ART, the ART 
should be continued and the patient should be initiated on histoplasmosis treat-
ment immediately. However if the patient is not receiving ART, a two-week delay is 
encouraged before starting ART while the patient is on antifungal therapy (ampho-
tericin B or itraconazole) as per the guidelines [14].
4. Conclusions
Itraconazole alone is used for the treatment of mild forms of histoplasmosis and 
as a step-down therapy in severe disease and for secondary prophylaxis to prevent 
relapse in the immunocompromised after induction therapy with amphotericin 
B. Moderate-to-severe acute pulmonary histoplasmosis as well as acute progressive 
disseminated histoplasmosis require intravenous amphotericin B therapy for at least 
2 weeks (4–6 weeks if meningeal involvement) or until a patient can tolerate oral 
therapy, then oral itraconazole (or an alternative triazole) for at least 12 weeks (for 
acute pulmonary) or 12 months (for acute progressive disseminated histoplasmo-
sis). Chronic cavitary pulmonary histoplasmosis is treated with itraconazole for 
12–24 months. There is insufficient evidence to support the use of isavuconazole 
and the echinocandins for the treatment of histoplasmosis.
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